The problem 

End-stage liver disease is associated with a highly inflammatory and damaging systemic immune response that is unable to defend against bacterial and viral pathogens and is unable to maintain antitumoral immunity.

The approach 

To develop disease-specific host-targeted immunomodulatory strategies to rebalance this skewed equilibrium to restore a state of effective antipathogen and anticancer immunity and dampen injurious inflammatory processes.

Main discoveries and innovations

Identification of key therapeutic targets to restore immunological homeostasis in chronic liver disease.


Institute of Hepatology, Foundation for Liver Research, UK
Acting Director/Chief Scientific Officer (2020–present)

King's College London, UK
Adjunct Honorary Reader